Market Segmentation:
- By Pathogen
- Streptococcus pneumoniae
- Staphylococcus aureus
- Haemophilus influenzae
- Pseudomonas aeruginosa
- Klebsiella pneumoniae
- Chlamydophila pneumoniae
- Others
- By Testing
- Microbial culture
- Gram staining
- PCR
- Immunoassay
- Microscopy
- Others
- By Treatment
- Antibiotics
- Oxygen therapy
- Vaccines
- Pain relievers
- Cough medicine
- Mechanical ventilation
- Others
- By End-User
- Hospitals
- Clinics
- Diagnostic centers
- Research institutes
- Others
- By Distribution Channel
- Hospital pharmacies
- Retail pharmacies
- Online pharmacies
- Others
- By Regions
- North America
- U.S.
- Canada
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Middle East & Africa
- GCC Countries
- Israel
- South Africa
- North Africa
- Central Africa
- Rest of the Middle East
- North America
Frequently Asked Questions
The current market size of the Bacterial Pneumonia industry is around USD 2.8 billion in 2023.
Rising prevalence of bacterial pneumonia, Growing geriatric population, Advancements in rapid diagnostics, Increasing healthcare expenditure, Favorable government policies, Product launches and approvals, Rising vaccine adoption, Growing awareness about pneumonia, Healthcare infrastructure improvements
Rising geriatric population, Growing prevalence of chronic respiratory disease, Increased exposure to bacterial infections, Advances in pneumonia vaccines, Demand for point-of-care diagnostics, Investments in biomarker research, Entry of AI and machine learning in pneumonia diagnosis, Development of new classes of antibiotics, Rising healthcare spending on pneumonia treatment
The leading component segment in the Bacterial Pneumonia Market is the antibiotics segment (widely used for treating bacterial pneumonia infections).
Pfizer, GlaxoSmithKline, Merck, Sanofi, Novartis, Johnson & Johnson, AstraZeneca, Eli Lilly, Abbott, F. Hoffmann-La Roche, Bayer, Bristol-Myers Squibb, Teva Pharmaceutical, Astellas Pharma, Daiichi Sankyo, Becton Dickinson, bioMérieux, Thermo Fisher Scientific, Siemens Healthineers, Danaher
The market is expected to grow at a CAGR of 3.5% from USD 2.8 billion in 2023 to USD 3.7 billion in 2031.
Rising geriatric population, Growing prevalence of chronic respiratory diseases, Increased exposure to bacterial infections, Advances in pneumonia vaccines, Demand for point-of-care diagnostics, Investments in biomarker research